Zealand Pharma Hosts Capital Market Day: Accelerating the Late Stage Pipeline

  • Four late stage programs with best-in-class potential and attractive risk profiles for rare diseases and diabetes
  • Ambition to become a world leader in specialty gastrointestinal and metabolic diseases has been established


Copenhagen 25 January, 2018 - Zealand Pharma A/S (Zealand) will host a Capital Market Day in New York, starting at 12:30 pm ET (6.30 pm CET), to highlight a year with substantial progress. Management will provide an update on the business and elaborate on why 2018 is set to be a transformational year for Zealand.

Two distinguished key opinion leaders will also provide presentations on the day: Dr. David F. Mercer, Professor of Surgery at University of Nebraska Medical Center, discussing the unmet needs of short bowel syndrome and Dr. Jessica Castle, Associate Professor at Oregon Health and Science University, providing a clinician's perspective on glucagon.

Topics of the day include:

  • Business highlights: In 2017, Zealand has delivered major advancements in the clinical pipeline, continuing the transformation towards a fully integrated biotech company. The financial strength, with increasing revenue from commercial products and partnerships, enables four late stage programs to advance towards launch into major markets in 3-4 years.
  • Our peptide platform: Zealand is a world leader in optimizing analogs of endogenous peptides to create novel medicines. We have a promising pre-clinical portfolio of mono, dual and triple agonist peptides with options to bring new candidates into clinical development in 2019/2020.
  • Glepaglutide: A best-in-class GLP-2 analog with life-changing potential for patients with short bowel syndrome is progressing into Phase 3 in 2018 with a once-weekly dosing opportunity.
  • Dasiglucagon: A novel stable liquid glucagon analog in development for three distinct products:
  • Treatment of congenital hyperinsulinism, with Phase 3 initiation planned for 2018, following FDA approval of Zealand's Investigational New Drug (IND) application.
  • Rescue treatment for severe hypoglycemia in the Hypopal® auto-injector, with Phase 3 results expected in 2018 and potential to more than double the glucagon market for rescue treatment.
  • Treatment of diabetes using dual-hormone pump systems containing dasiglucagon, with initiation of a Phase 2b in 2018 and opportunity to establish a paradigm shift in Type 1 diabetes.
  • Driving success in 2018 and beyond: 2018 is set to be a transformational year for Zealand with multiple value drivers. We will deliver strong progress in the late stage pipeline, with two programs starting Phase 3, one program reporting Phase 3 results, and two partnered programs in obesity expecting to conclude Phase 1. Additionally, new high-value partnerships are expected across the portfolio. Based on our financial strength, we can manage our clinical development costs, and we possess the ability to execute on our business priorities to become a world leader in specialty gastrointestinal and metabolic diseases.


All sessions of the Capital Market Day in New York will be webcast live on link http://lifesci.rampard.com/20180125/ and a replay will be made available on zealandpharma.com

Monday 29 January 2018, Zealand will host a second Capital Market Day at our headquarters in Glostrup, Denmark. The event will start at 13:30 CET. Registration by mail to jwr@zealandpharma.com.

For further information, please contact:
Britt Meelby Jensen, President and CEO
Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com
Mats Blom, Executive Vice President, Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a pipeline of fully owned product candidates focusing on specialty gastrointestinal and metabolic diseases and a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.



Back to news